Moomoo AIのまとめ
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in its latest quarterly report. However, the company has disclosed stock-based compensation for stock options, which increased from $149,153 in the nine months ended January 31, 2023, to $326,578 in the same period in 2024. Deferred tax assets have also been reported, with a net operating loss carryforwards of approximately $52 million as of January 31, 2024, up from $46 million the previous year. The company has entered into significant business development agreements, including a multi-year collaboration with Rutgers University and multiple definitive license agreements with Mount Sinai for AI cardiovascular algorithms. Heart Test Laboratories plans to submit a 510(k) FDA submission for its MyoVista device and is aiming for clearance within the 2024 calendar year. The company has also received patent allowances in various regions and has entered into financial agreements to support its operations, including an Equity Distribution Agreement with Maxim Group LLC.
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in its latest quarterly report. However, the company has disclosed stock-based compensation for stock options, which increased from $149,153 in the nine months ended January 31, 2023, to $326,578 in the same period in 2024. Deferred tax assets have also been reported, with a net operating loss carryforwards of approximately $52 million as of January 31, 2024, up from $46 million the previous year. The company has entered into significant business development agreements, including a multi-year collaboration with Rutgers University and multiple definitive license agreements with Mount Sinai for AI cardiovascular algorithms. Heart Test Laboratories plans to submit a 510(k) FDA submission for its MyoVista device and is aiming for clearance within the 2024 calendar year. The company has also received patent allowances in various regions and has entered into financial agreements to support its operations, including an Equity Distribution Agreement with Maxim Group LLC.
医療関連テクノロジー会社のHeart Test Laboratoriesは、2023年1月31日の9か月間での$149,153から、2024年の同じ期間に$326,578に増加したオプション株式報酬を開示しているが、売上高、営業利益、純利益、または希薄化後の一株当たり利益など、具体的な財務業績メトリックは提供していない。ただし、2024年1月31日時点で約5200万ドルの純営業損失繰越を持つ先行課税資産が報告されており、前年の4600万ドルからアップした。Heart Test Laboratoriesは、ラトガーズ大学との長期の共同作業契約、およびAI心血管アルゴリズムのマウントシナイとの複数...すべて展開
医療関連テクノロジー会社のHeart Test Laboratoriesは、2023年1月31日の9か月間での$149,153から、2024年の同じ期間に$326,578に増加したオプション株式報酬を開示しているが、売上高、営業利益、純利益、または希薄化後の一株当たり利益など、具体的な財務業績メトリックは提供していない。ただし、2024年1月31日時点で約5200万ドルの純営業損失繰越を持つ先行課税資産が報告されており、前年の4600万ドルからアップした。Heart Test Laboratoriesは、ラトガーズ大学との長期の共同作業契約、およびAI心血管アルゴリズムのマウントシナイとの複数の定義的なライセンス契約を含む重要なビジネス開発契約を締結している。Heart Test Laboratoriesは、MyoVistaデバイスのFDAの510(k)出願を計画し、2024年のカレンダー年内に承認を目指している。同社はまた、様々な地域で特許を受け入れ、最大グループLLCとのエクイティ・ディストリビューション・アグリーメントを含む、その運用を支援する金融協定にも参加している。
役に立った
役に立たない
